PER-005-22尚未招募2 期
A PHASE IIC TRIAL OF CLOFAZIMINE- AND RIFAPENTINE-CONTAINING TREATMENT SHORTENING REGIMENS IN DRUG-SUSCEPTIBLE TUBERCULOSIS: THE CLO-FAST STUDY.
Instituto Nacional de Alergias y Enfermedades Infecciosas NIAID0 个研究点目标入组 0 人开始时间: 2023年5月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:
- •At least one sputum specimen positive for M. tuberculosis by molecular TB assay (Xpert) or line probe assay [LPA])
- •At least one sputum specimen positive (1+ or greater) for acid-fast bacilli (AFB) on smear microscopy
- •Pulmonary TB diagnosed without known INH resistance (e.g., by LPA or Xpert MTB/XDR) and without known RIF resistance (e.g., by either LPA or Xpert MTB/RIF or Ultra).
- •Aged =18 years.
- •Ability and willingness of participant to provide informed consent.
- •Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to entry
- •HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection.
- •For participants living with HIV, CD4+ cell count =100 cells/mm3, obtained within 30 days prior to study entry at any network-approved non-US laboratory that is IQA certified.
- •For participants living with HIV must be currently receiving or planning to initiate ART at or before study week 8.
- •A verifiable address or residence readily accessible to facilitate directly observed therapy (DOT), and willingness to inform the study team of any change of address during the treatment and follow-up period.
- •The following laboratory values obtained at or within 5 days prior to entry by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs.
- •Serum or plasma alanine aminotransferase (ALT) =3 times the upper limit of normal (ULN)
- •Serum or plasma total bilirubin =2.5 times ULN
- •Serum or plasma creatinine =2 times ULN
- •Serum or plasma potassium =3.5 mEq/L and =5.5 mEq/L
- •Absolute neutrophil count (ANC) =650/mm3
- •Hemoglobin =7.0 g/dL
- •Platelet count =50,000/mm3
- •For study candidates of child-bearing
排除标准
- •More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
- •Pregnant or breast-feeding.
- •Unable to take oral medications.
- •Current receipt of clofazimine or bedaquiline or known receipt of clofazamine or bedaquiline at any time in the past.
- •QTcF interval >450 ms for men or >470 ms for women within 30 days prior to entry.
- •Weight <40 kg.
- •Current or planned use within 6 months following enrollment of one or more of the following medications: HIV protease inhibitors, HIV entry and fusion inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (other than EFV), elvitegravir/cobicistat, bictegravir, quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine.
- •Current extrapulmonary TB, in the opinion of the site investigator.
- •Current or history of known personal or family long QT syndrome.
- •Known allergy/sensitivity or any hypersensitivity to components of study TB drugs or their formulation.
- •Active drug, alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- •Known history of acute intermittent porphyria.
- •Other medical conditions (e.g., severe uncontrolled diabetes, liver or kidney disease, blood disorders, peripheral neuritis, chronic diarrhea) in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.
研究者
相似试验
尚未招募
2 期
A5362: The CLO-FAST StudyCTRI/2021/04/033189IH DAIDS
终止
2 期
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST StudyHIVTuberculosisNCT04311502National Institute of Allergy and Infectious Diseases (NIAID)104
进行中（未招募）
1 期
A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML). - CLARAMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaAcute Myeloid LeukemiaEUCTR2008-000668-18-FRHospices Civils de Lyon
进行中（未招募）
2 期
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)Mycobacterium Avium ComplexNCT02968212Oregon Health and Science University102
进行中（未招募）
1 期
A study with a combination of two anticancer drugs as a salvage therapy for patients, affected by acute leukaemia aiming at lymphocites, adult not respondent to previous therapies or with a relapsing leukaemia.Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019742-12-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO